0001326190-26-000018
SEC filingAltimmune, Inc. reported a net loss of $88.1 million for fiscal year 2025, an improvement of 7% compared to a net loss of $95.1 million in 2024. The company generated minimal revenue of $41,000, primarily from grants, and has not generated any product sales to date. Total operating expenses decreased by 8% to $94.5 million, driven by a 19% reduction in research and development expenses to $66.4 million, partially offset by a 34% increase in general and administrative expenses to $28.1 million. The company ended the year with $273.5 million in cash, cash equivalents, restricted cash, and short-term investments, and management believes this is sufficient to fund operations for at least twelve months. Key developments include the initiation of clinical trials for pemvidutide in AUD and ALD, completion of the IMPACT Phase 2b trial in MASH, and securing a $125 million term loan facility.
Altimmune reported a net loss of $88.1 million for fiscal year 2025, representing a 7% improvement from the $95.1 million net loss in 2024. Revenue was minimal at $41,000, consisting entirely of government and foundation grants, with no product sales generated. The company's loss from operations was $94.5 million, an 8% improvement from $103.2 million in 2024. Research and development expenses decreased by 19% to $66.4 million, while general and administrative expenses increased by 34% to $28.1 million. Other income contributed $5.7 million, primarily from interest income of $7.5 million offset by interest expense of $1.6 million. The company ended the year with an accumulated deficit of $649.5 million.
The company has not generated any revenue from product sales to date. The $41,000 in revenue for 2025 represents government and foundation grants supporting specific research projects, compared to $20,000 in similar grants in 2024. All of the company's revenue comes from non-product sources, and there is no assurance of future product revenue. The company's business model remains entirely dependent on the successful development and regulatory approval of its product candidates, particularly pemvidutide for MASH, AUD, and ALD indications.
With minimal revenue and significant operating expenses, the company operates at substantial losses. The 8% improvement in operating loss was driven primarily by reduced research and development spending, which decreased by $15.8 million or 19% year-over-year. This reduction was partially offset by increased general and administrative expenses, which rose by $7.1 million or 34% due to higher professional services and stock compensation costs. The company's cost structure remains heavily weighted toward research and development, which represented 70% of total operating expenses in 2025. Gross margin analysis is not applicable given the absence of product sales.
The company used $67.5 million in operating cash flow during 2025, an improvement from $79.8 million used in 2024. Investing activities used $132.5 million primarily for purchases of short-term investments, while financing activities provided $206.8 million from equity offerings and debt proceeds. The company ended the year with $273.5 million in cash, cash equivalents, restricted cash, and short-term investments, providing liquidity for at least twelve months of operations. Total assets were $279.9 million, with current assets of $278.2 million primarily consisting of cash and short-term investments. Total liabilities were $55.0 million, including a $34.3 million term loan. Stockholders' equity was $224.9 million.
Management believes current cash resources are sufficient to fund operations for at least twelve months from the issuance of the financial statements. The company plans to increase research and development expenses for the foreseeable future as it continues development of clinical and preclinical candidates, including Phase 3 trials for pemvidutide in MASH and clinical trials for AUD and ALD. The company will need to pursue additional equity or debt financing, partnership arrangements, or program monetization to address long-term capital needs. Risk factors include dependence on pemvidutide development, regulatory uncertainties, need for additional financing, and lack of product revenue. The company has shelf registrations allowing for up to $400 million in securities offerings and an active at-the-market offering program with $174.2 million remaining capacity.